Indaptus Therapeutics, Inc. (INDP)
1.15
+0.02
(+1.77%)
USD |
NASDAQ |
Sep 02, 16:00
1.15
0.00 (0.00%)
After-Hours: 20:00
Indaptus Therapeutics EPS Diluted (Quarterly) : -0.0155 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0155 |
| March 31, 2026 | -0.2319 |
| December 31, 2025 | -3.743 |
| September 30, 2025 | -2.984 |
| June 30, 2025 | -9.095 |
| March 31, 2025 | -0.3214 |
| December 31, 2024 | -10.43 |
| September 30, 2024 | -0.3227 |
| June 30, 2024 | -0.47 |
| March 31, 2024 | -0.4509 |
| December 31, 2023 | -0.4765 |
| September 30, 2023 | -0.4669 |
| June 30, 2023 | -0.3863 |
| March 31, 2023 | -0.5063 |
| December 31, 2022 | -0.4419 |
| September 30, 2022 | -0.4197 |
| June 30, 2022 | -0.4644 |
| March 31, 2022 | -0.4075 |
| December 31, 2021 | -0.3894 |
| September 30, 2021 | -0.8054 |
| June 30, 2021 | -29.69 |
| March 31, 2021 | -35.27 |
| December 31, 2020 | -44.36 |
| September 30, 2020 | -1777.01 |
| June 30, 2020 | -3.753 |
| Date | Value |
|---|---|
| March 31, 2020 | -6.598 |
| December 31, 2019 | -14.61 |
| September 30, 2019 | -48.64 |
| June 30, 2019 | -24.05 |
| March 31, 2019 | -25.64 |
| December 31, 2018 | -30.34 |
| September 30, 2018 | -22.10 |
| June 30, 2018 | -27.20 |
| March 31, 2018 | -32.92 |
| December 31, 2017 | -31.20 |
| September 30, 2017 | -32.00 |
| June 30, 2017 | -37.60 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | -20.84 |
| September 30, 2015 | -12.89 |
| June 30, 2015 | -12.82 |
| March 31, 2015 | -28.17 |
| December 31, 2014 | -0.4179 |
| September 30, 2014 | -0.4549 |
| June 30, 2014 | -0.4619 |
| March 31, 2014 | -0.4577 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cypherpunk Technologies, Inc. | 0.1812 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.795M |
| Total Expenses (Quarterly) | 1.795M |
| Enterprise Value | 139.01M |
| Earnings Yield | -606.5% |
| Normalized Earnings Yield | -581.86 |